Utilization of Non-Drug-Eluting Devices for Inpatient Percutaneous Coronary Intervention in the United States.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
01 01 2023
Historique:
received: 24 08 2022
revised: 11 09 2022
accepted: 29 09 2022
pubmed: 4 11 2022
medline: 7 12 2022
entrez: 3 11 2022
Statut: ppublish

Résumé

There is a paucity of data on the contemporary use of non-drug-eluting devices (balloon angioplasty or bare-metal stents) in contemporary percutaneous coronary intervention (PCI) in the United States. We utilized the Nationwide Readmissions Database to identify patients hospitalized to undergo PCI with non-drug-eluting devices from 2016 to 2019. The main outcome of interest was the trends in utilization over the study years. Among 1,870,262 PCI procedures, 127,810 (6.8%) were performed with non-drug-eluting devices; 72% of these were in the setting of acute myocardial infarction (MI). The use of non-drug-eluting devices decreased throughout the study period from 12.9% of all PCI in the first quarter of 2016 to 3.4% in the last quarter of 2019 (p <0.001). Factors associated with their use included advanced age and high bleeding risk. Only a small percentage were used as a bridge to coronary artery bypass graft surgery (2%) and for treatment of in-stent restenosis (3%). The in-hospital mortality was 5.8% for the entire cohort and 6.6% when the indication for use was an acute MI. In patients presenting with an acute MI, reinfarction within 30 days was common and occurred in 18% of the patients. In conclusion, the use of non-drug-eluting devices in PCI in the United States decreased from 2016 to 2019. Factors associated with their use included old age and high bleeding risk. Due to suboptimal outcomes in patients currently being treated with non-drug-eluting devices, there remains an unmet clinical need for alternative treatment options.

Identifiants

pubmed: 36328830
pii: S0002-9149(22)01062-1
doi: 10.1016/j.amjcard.2022.09.033
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

209-215

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Ramy Sedhom (R)

Division of Cardiology, Loma Linda University Health, Loma Linda, California.

Bernardo Cortese (B)

Foundation for Cardiovascular Research and Innovation, Milan, Italy.

Mohamed Khedr (M)

Faculty of Medicine, Menoufia University, Menoufia, Egypt.

Aditya Bharadwaj (A)

Division of Cardiology, Loma Linda University Health, Loma Linda, California.

Emmanouil S Brilakis (ES)

Division of Cardiology, Minneapolis Heart Institute, Minneapolis, Minnesota.

Ashish Pershad (A)

Division of Cardiology, Chandler Regional Medical Center, Chandler, Arizona.

Mir B Basir (MB)

Department of Cardiology, Henry Ford Hospital, Detroit, Michigan.

Khaldoon Alaswad (K)

Department of Cardiology, Henry Ford Hospital, Detroit, Michigan.

Robert W Yeh (RW)

Department of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Michael Megaly (M)

Department of Cardiology, Henry Ford Hospital, Detroit, Michigan. Electronic address: michaelmegaly3@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH